Muthusamy Selvaraj
VP, Innovation & Emerging Markets | Tata Elxsi
Muthusamy is a seasoned technology and engineering leader with extensive experience in digital transformation, enterprise technology strategy, product engineering, and innovation-led business growth. With a strong background in building and scaling technology organizations, he has led transformative initiatives across global enterprises, driving operational excellence and enabling next-generation digital capabilities.
Recognized for his expertise in enterprise platforms, cloud technologies, engineering transformation, and emerging digital ecosystems, Muthusamy has worked closely with business and technology leaders to modernize operations, accelerate innovation, and create scalable, future-ready solutions. His leadership spans strategic transformation programs, technology consulting, and the development of high-performing engineering teams.
Passionate about innovation and technology-driven business impact, Muthusamy actively contributes to industry conversations around digital engineering, intelligent enterprises, and the evolving role of technology in shaping future businesses.
All Sessions by Muthusamy Selvaraj
Engineering Theatre
AI‑Native Digital Thread for MedTech: From Code Traceability to Material DNA
Two years ago, a regulatory crisis forced a different question — not how to automate compliance, but how to amplify the experts who understand it. The more you automate with black-box AI, the more you erode the expertise regulators demand. ThELix OS resolves that tension: autonomous agents handling the workflow, domain experts governing every decision.
Two acts. One platform.
ViTel™ transforms fragmented material records, supplier data, and compliance obligations into a living Material DNA layer across the product lifecycle. AnaTel™ reimagines not retrofits — how regulated software is built: FDA submission acceleration, bidirectional traceability, and clinical evidence intelligence.
Real outcomes: 70% reduction in regulatory research labor. 60% reduction in clinical review effort. 72 hours versus eight weeks on SaMD change assessment.
Compliance is not the opposite of competitive advantage. Done right, it is the source of it.
For: Engineering, regulatory, QA, and digital health leaders in medical device and SaMD organizations.
Resources
Subscribe to MassDevice
Advertise with us
For registration or logistic questions, contact events@wtwhmedia.com
Sponsorship Opportunities
Colleen Sepich
Events Sales Director
csepich@wtwhmedia.com
857-260-1360
Heather Herbert
Event Sales Manager
hherbert@wtwhmedia.com
512-760-0570